PEPTIDE SERVICES
Project-Based Peptide Development
Raysun Biopharma supports peptide projects through sequence review, synthesis-route assessment, purification strategy and analytical planning. Each program is evaluated according to its target sequence, intended use, quantity and quality requirements.
Our biopharmaceutical manufacturing platform in Vientiane, Laos is currently under development. Available scope, manufacturing location, specifications, documentation and delivery schedules are confirmed during technical and quality review.
Peptide Project Capabilities
Sequence & Feasibility Review
- Sequence complexity assessment
- Physicochemical property review
- Initial project scope definition
Synthesis & Process Development
- Project-specific synthesis strategy
- Process parameter evaluation
- Cleavage and isolation planning
Purification Strategy
- Chromatographic purification planning
- Impurity-profile assessment
- Isolation and lyophilization strategy
Analytical Characterization
- Identity and purity testing plan
- Chromatographic and MS method planning
- Project documentation requirements
Modification & Conjugation Evaluation
- Modification feasibility assessment
- Peptide conjugation and functionalization review
- Scope confirmed on a project-by-project basis
Scale-Up & Technology Transfer
- Development and scale-up planning
- Process and analytical method transfer
- OEM and CDMO project evaluation
QUALITY & ANALYTICS
Peptide Quality & Analytical Strategy
Quality requirements are defined during project evaluation according to the peptide’s intended use, development stage and agreed product specifications. The analytical scope may include identity, purity, impurity profile and other project-specific quality attributes.
Methods, acceptance criteria, documentation requirements and testing arrangements are confirmed in the approved project proposal and quality agreement.
Core Analytical Planning Areas
- Chromatographic method planning for purity and impurity profiling
- Mass spectrometry-based identity confirmation
- Peptide content and physicochemical attribute assessment
- Reference standard and sample-management planning
- Analytical method transfer and verification planning
Project-Specific Testing Considerations
Depending on the material type and project stage, additional testing may be evaluated and confirmed separately.
- Amino acid analysis
- Peptide sequence confirmation by mass spectrometry
- Counter-ion determination
- Residual solvent and moisture assessment
- Solubility and stability study design
- Endotoxin, bioburden or sterility testing for applicable materials
- Other project-specific analytical requirements
Important: The final test panel, specifications, method status and reporting package are defined on a project-by-project basis. Availability remains subject to facility qualification, regulatory readiness and the agreed project scope.
PURITY OPTIONS
Peptide Purity Levels for Project Planning
Purity targets are selected according to the peptide’s intended use, development stage and analytical requirements. Final specifications and test methods are confirmed during technical review.
Important: Purity level alone does not determine GMP, clinical or commercial suitability. GMP manufacturing, release specifications, documentation and regulatory requirements are evaluated separately for each project.
| ≥70% Preliminary ScreeningSuitable for early, non-quantitative research and feasibility work. | ≥80% Research GradeDesigned for routine discovery research and qualitative biochemical studies. | ≥95% High-Purity Research GradeRecommended for sensitive, quantitative and reproducible research applications. | ≥98% Advanced Research GradeIntended for projects requiring stringent purity and structural characterization. |
|---|---|---|---|
| Crude peptide screening | Enzyme–substrate screening | Quantitative biochemical assays | High-resolution mass spectrometry |
| Initial method development | Peptide blocking and inhibition research | Receptor–ligand binding studies | NMR and structural research |
| Conjugation feasibility studies | Epitope mapping and peptide arrays | Cell-based research | Crystallography-related preparation |
| Preliminary antibody-generation studies | Affinity and pull-down studies | Analytical method development | Advanced impurity characterization |
| High-throughput sequence evaluation | General in-vitro assay development | Research reference-material preparation | Preclinical project evaluation |
| Final scope confirmed during technical review | Final scope confirmed during technical review | Final scope confirmed during technical review | Final scope confirmed during technical review |
Custom Peptide Synthesis FAQs
- What information is needed to evaluate a custom peptide project?
-
Please provide the target sequence, terminal configuration, required modifications, desired purity, quantity, intended use and analytical requirements. Any preferred delivery format, documentation needs and target timeline should also be included. If some specifications have not yet been defined, our team can support the initial technical assessment.
- How should I select the appropriate peptide purity level?
-
The appropriate purity target depends on the intended application, development stage and sensitivity of the analytical or biological method. Preliminary screening projects may use lower-purity material, while quantitative, structural or advanced research generally requires higher purity. Final specifications and test methods are confirmed during project review.
- Can Raysun evaluate modified or conjugated peptide projects?
-
Raysun can evaluate modification and conjugation requirements on a project-by-project basis. Please provide the modification type, preferred position, conjugation partner and intended application. Sequence complexity, synthesis feasibility, purification strategy and analytical requirements will be reviewed before the project scope is confirmed.
- What analytical documentation may be included with a peptide project?
-
The project-specific documentation package may include agreed analytical methods, identity and purity results, chromatographic data, mass-spectrometry data and other specified quality information. The final testing panel, acceptance criteria and reporting format are defined in the approved project proposal.
- Does ≥98% peptide purity mean that the material is GMP grade?
-
No. Purity alone does not determine GMP status or clinical suitability. GMP material requires qualified facilities, controlled manufacturing processes, approved specifications, appropriate analytical methods, quality oversight and release documentation. GMP requirements are evaluated separately during project planning.
- How are project timelines and manufacturing arrangements confirmed?
-
Timelines depend on sequence complexity, modification requirements, scale, raw-material availability, purification strategy and analytical scope. Manufacturing location and service availability are confirmed after technical and quality review. Raysun Biopharma’s manufacturing platform in Vientiane, Laos is currently under development.
- What is the difference between gross and net peptide weight?
-
Gross weight includes the peptide together with associated water, salts, counter-ions and other non-peptide components. Net peptide weight refers only to the actual peptide content. When net peptide content is important for an application, the required calculation or testing approach should be specified during project review.